InvestSMART

Imugene Limited (ASX: IMU) - Announcements

Current share price for IMU : $0.063 0.002 (3.08%)+

ASX company news and announcements for Imugene Limited (IMU) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Imugene Limited (IMU) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Imugene Limited (IMU), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Imugene Limited (IMU)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$34 Notification regarding unquoted securities - IMU 23 Dec 2021 5:11PM $0.410 $0.063 fallen by 84.63%
$34 Application for quotation of securities - IMU 23 Dec 2021 4:58PM $0.410 $0.063 fallen by 84.63%
$34 Change of Director's Interest Notice - CW 20 Dec 2021 4:51PM $0.420 $0.063 fallen by 85%
$34 Appendix 2A and IMUOB Option Underwriting Agreement 20 Dec 2021 9:25AM $0.455 $0.063 fallen by 86.15%
$34 Change in substantial holding - PH 15 Dec 2021 5:58PM $0.455 $0.063 fallen by 86.15%
$34 Imugene HER-Vaxx Immunotherapy Patent Allowed in China 14 Dec 2021 9:38AM $0.520 $0.063 fallen by 87.88%
$34 Change of Director's Interest Notice - PH 13 Dec 2021 6:42PM $0.520 $0.063 fallen by 87.88%
$34 FDA IND APPROVAL FOR THE PHASE 2 CLINICAL TRIAL OF HER-VAXX 13 Dec 2021 8:47AM $0.515 $0.063 fallen by 87.77%
$34 FDA IND APPROVAL FOR ONCOLYTIC VIROTHERAPY VAXINIA 13 Dec 2021 8:47AM $0.515 $0.063 fallen by 87.77%
$34 Appendix 2A 10 Dec 2021 5:31PM $0.515 $0.063 fallen by 87.77%
$34 Change in Joint Company Secretary 8 Dec 2021 5:03PM $0.480 $0.063 fallen by 86.88%
$34 Update on Clinical Trial of Oncolytic Virotherapy CHECKvacc 7 Dec 2021 8:50AM $0.475 $0.063 fallen by 86.74%
$34 Appendix 2A 6 Dec 2021 8:33AM $0.510 $0.063 fallen by 87.65%
$34 S&P DJI Announces December 2021 Quarterly Rebalance 3 Dec 2021 5:00PM $0.510 $0.063 fallen by 87.65%
$34 Appendix 2A 26 Nov 2021 7:07PM $0.510 $0.063 fallen by 87.65%
$34 Results of Meeting Percentages 23 Nov 2021 8:52AM $0.530 $0.063 fallen by 88.11%
$34 Final Director's Interest Notice (AH) 22 Nov 2021 9:10AM $0.565 $0.063 fallen by 88.85%
$34 Ceasing to be a Director 22 Nov 2021 9:09AM $0.565 $0.063 fallen by 88.85%
$34 Change of Director's Interest Notice (AH) 22 Nov 2021 9:02AM $0.565 $0.063 fallen by 88.85%
$34 Results of Meeting 19 Nov 2021 6:14PM $0.565 $0.063 fallen by 88.85%
$34 Application for quotation of securities - IMU 19 Nov 2021 5:41PM $0.565 $0.063 fallen by 88.85%
$34 AGM Presentation 19 Nov 2021 10:34AM $0.555 $0.063 fallen by 88.65%
$34 Notice Under Section 708A 16 Nov 2021 5:44PM $0.595 $0.063 fallen by 89.41%
$34 Application for quotation of securities - IMU 16 Nov 2021 5:38PM $0.595 $0.063 fallen by 89.41%
$34 Clinical Trial Supply Agreement with Merck KGaA and Pfizer 16 Nov 2021 8:15AM $0.575 $0.063 fallen by 89.04%

501 - 525 of 1200 results

Page 21 of 48

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.